Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

T-cell gene therapy successful in early clinical trial

24 February 2014

By Chris Hardy

Appeared in BioNews 743

Researchers trialling a gene therapy-based treatment for leukaemia have said the results go beyond anything they could have hoped for in their 'wildest dreams'.

The therapy involves the genetic modification of a sufferer's white blood cells so that they are able to fight cancerous cells in the blood.

Researchers at the Memorial Sloan Kettering Cancer Center in New York, USA, performed the largest ever clinical trial of the technique on 16 leukaemia patients who had relapsed after chemotherapy treatment. Fourteen went into remission, comparing favourably with chemotherapy, which the researchers say is effective for just 30 percent of relapsed patients.

'We found that this type of therapy […] has outcomes that far exceed anything we could have thought or dreamed of in our wildest dreams', Dr Renier Brentjens, the study's lead author, told CBS New York. 'It's extremely gratifying to witness the astonishing results first hand'.

The study participants all had a type of cancer known as adult B-cell acute lymphoblastic leukemia (B-ALL), an aggressive cancer affecting a type of white blood cells known as B-cells.

For common viruses such as the flu, another type of white blood cell called T-cells fight the virus. But T-cells aren't able to detect cancerous cells affected in B-ALL, and so don't destroy them.

To overcome this problem, Dr Brentjens and his colleagues took a sample of each participant's T-cells. They then used gene therapy technology 'to redirect the immune cells to recognise [and destroy] the cancer', he told CBS New York.

The ultimate goal in the treatment of adult B-ALL is a bone marrow transplant, the only known cure for the disease. Without a successful transplant, most patients will die, but transplants can only be given to people whose cancer is in complete remission. T-cell gene therapy could therefore be a valuable option for those patients who have had no success with conventional therapies.

However the technique can cause significant side effects, including plummeting blood pressure, fevers, muscle pain and difficulties in breathing. Some patients are affected worse than others, and the study suggests diagnostic criteria that may help to identify who might be most vulnerable.

The study confirms the findings of a smaller trial on just five patients undertaken by the same research group (reported in BioNews 698). The therapy will need to be thoroughly tested in larger trials before it could become widely available, and this process will take several years.

The study was published in the journal Science Translational Medicine.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

04 September 2017 - by Meetal Solanki 
The world's first cancer treatment which uses a patient's own genetically modified immune cells has been approved...
12 June 2017 - by Ebtehal Moussa 
Two trials of a new gene therapy have successfully treated blood cancers in patients who were unresponsive to standard treatment...
18 May 2015 - by Dr Nicola Davis 
Researchers have discovered a pattern in 11 genes that could make it quick and easy to diagnose sepsis, a serious life-threatening condition...
01 December 2014 - by Dr Anna Cauldwell 
Genetics researchers in the US have identified mutations that significantly increase the likelihood that an individual will go on to develop blood cancer...
03 March 2014 - by Rhys Baker 
A recovering teenage cancer patient is a lead author of a study into the rare form of liver cancer she contracted. The research, published in Science, identified a key mutation that may explain the uncontrolled growth of the tumour...

16 December 2013 - by Dr Rachel Brown 
Gene therapy trials using engineered immune cells have shown considerable progress in treating blood disorders, according to findings presented at the American Society of Hematology's annual meeting...
19 August 2013 - by Siobhan Chan 
Human stem cells have been reprogrammed to form cancer-targeting immune cells that were shown to stop tumour growth in mice...
25 March 2013 - by John Brinsley 
Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life saving potential'....
07 January 2013 - by Dr Greg Ball 
Immune cells that can recognise and kill cancer cells have been grown from induced pluripotent stem cells (iPSCs)...

HAVE YOUR SAY
Be the first to have your say.

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation